Search

Your search keyword '"Seneschal, J"' showing total 736 results
Start Over Author "Seneschal, J"
736 results on '"Seneschal, J"'

1. POS1186 EVALUATION OF A SCREENING TEST FOR VEXAS SYNDROME USING THE BORDEAUX UNIVERSITY HOSPITAL BIOMEDICAL DATA WAREHOUSE

Author

Hamon, A., primary, Jean, A., additional, Saraux, O., additional, Collinet, C., additional, Lazaro, E., additional, Seneschal, J., additional, Bidet, A., additional, Dulucq, S., additional, Sartre, C., additional, Schaeverbeke, T., additional, Poursac, N., additional, Richez, C., additional, Kostine, M., additional, Mehsen-Cetre, N., additional, and Truchetet, M. E., additional

Published
2024
Full Text
View/download PDF

5. Baseline patient characteristics, physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis in France treated with dupilumab: Real-world insights 1 year into the GLOBOSTAD multinational prospective observational study

Author

Fougerousse, A.C., primary, Tauber, M., additional, Seneschal, J., additional, Du-Thanh, A., additional, Tetart, F., additional, Becherel, P.A., additional, Wu, J., additional, Ardeleanu, M., additional, and Bosman, K., additional

Published
2024
Full Text
View/download PDF

6. PCR256 Correlation of Patient-Reported Vitiligo Noticeability Scale With Physician-Assessed Facial Vitiligo Area Scoring Index Responses: Post Hoc Analyses From the True-V Trials of Ruxolitinib Cream in Vitiligo

Author

Wolkerstorfer, A., primary, Passeron, T., additional, Rosmarin, D., additional, Sebastian, M., additional, Desai, S.R., additional, Alam, M.S., additional, Seneschal, J., additional, Butler, K., additional, Bibeau, K., additional, Ren, H., additional, and Pandya, A.G., additional

Published
2023
Full Text
View/download PDF

13. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce

Author

Bosma, A. L., Musters, A. H., Bloem, M., Gerbens, L. A. A., Middelkamp-Hup, M. A., Haufe, E., Schmitt, J., Barbarot, S., Seneschal, J., Staumont-Sallé, D., Johansson, E. K., Bradley, M., von Kobyletzki, Laura B., Vittrup, I., Ruge, I. Frier, Thyssen, Jacob P., Vestergaard, C., de Vega, M., García-Doval, I., Chiricozzi, A., Stingeni, Luca, Calzavara-Pinton, Piergiacomo, Ardern-Jones, M. R., Reynolds, N. J., Flohr, C., Spuls, P. I., Bosma, A. L., Musters, A. H., Bloem, M., Gerbens, L. A. A., Middelkamp-Hup, M. A., Haufe, E., Schmitt, J., Barbarot, S., Seneschal, J., Staumont-Sallé, D., Johansson, E. K., Bradley, M., von Kobyletzki, Laura B., Vittrup, I., Ruge, I. Frier, Thyssen, Jacob P., Vestergaard, C., de Vega, M., García-Doval, I., Chiricozzi, A., Stingeni, Luca, Calzavara-Pinton, Piergiacomo, Ardern-Jones, M. R., Reynolds, N. J., Flohr, C., and Spuls, P. I.

Abstract

BACKGROUND: the TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common goal to provide long-term real-world data on the effectiveness, safety and cost-effectiveness of therapies. A core dataset, consisting of domains and domain items with corresponding measurement instruments, has been developed to harmonize data collection. OBJECTIVES: we aimed to give an overview of the status and characteristics of the eight established TREAT registries, and to perform a mapping exercise to examine the degree of overlap and pooling ability between the national registry datasets. This will allow us to determine which research questions can be answered in the future by pooling data. METHODS: all eight registries were asked to share their dataset and information on the current status and characteristics. The overlap between the core dataset and each registry dataset was identified (according to the domains, domain items and measurement instruments of the TREAT core dataset). RESULTS AND CONCLUSIONS: a total of 4,702 participants have been recruited in the 8 registries as of 1st of May 2022. Of the 69 core dataset domain items, data pooling was possible for 69 domain item outcomes in TREAT NL (the Netherlands), 61 items in A-STAR (UK and Ireland), 38 items in TREATgermany (Germany), 36 items in FIRST (France), 33 items in AtopyReg (Italy), 29 items in Biobadatop (Spain), 28 items in SCRATCH (Denmark) and 20 items in SwedAD (Sweden). Pooled analyses across all registries can be performed on multiple important domain items, covering the main aims of analyzing data on the (cost-)effectiveness and safety of AE therapies. These results will facilitate future comparative or joint analyses.

Published
2023
Full Text
View/download PDF

17. CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

Author

Ezzedine, K, primary, Passeron, T, additional, Seneschal, J, additional, Rosmarin, D, additional, Grimes, P, additional, Harris, JE, additional, Desai, SR, additional, Lebwohl, M, additional, Ruer-Mulard, M, additional, Wolkerstorfer, A, additional, Kornacki, D, additional, Ren, H, additional, Butler, K, additional, Bibeau, K, additional, and Pandya, AG, additional

Published
2022
Full Text
View/download PDF

20. Efficacité de l’abrocitinib et du dupilumab sur les taux d’éosinophiles chez les patients atteints de dermatite atopique modérée à sévère et de comorbidités atopiques de type asthme et rhinite allergique : analyse post-hoc de JADE COMPARE

Author

Staumont-Sallé, D., primary, Chan, G., additional, Clibborn, C., additional, Feeney, C., additional, Bourne-Chastel, A., additional, Misery, L., additional, Nosbaum, A., additional, Seneschal, J., additional, Soria, A., additional, and Zhang, F., additional

Published
2022
Full Text
View/download PDF

24. Étude descriptive multicentrique des schémas d’adaptation en cas de réponse inadéquate au dupilumab dans la dermatite atopique en France

Author

Strizzolo, R., primary, Soria, A., additional, Jachiet, M., additional, Tauber, M., additional, Seneschal, J., additional, Clément, A., additional, Staumont-Sallé, D., additional, Barbarot, S., additional, Raison Peyron, N., additional, Viguier, M., additional, Mallet, S., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

25. Efficacité et tolérance des inhibiteurs de Janus kinase dans le traitement de la dermatite atopique modérée à sévère de l’adulte réfractaire à d’autres systémiques: expérience en vraie vie

Author

Vanlerberghe, J., primary, Dezoteux, F., additional, Martin, C., additional, Jachiet, M., additional, Soria, A., additional, Tétart, F., additional, Modeste-Duval, A.B., additional, Bursztejn, A.C., additional, Misery, L., additional, Aubin, F., additional, Lasek, A., additional, Leleu, C., additional, Du Thanh, A., additional, Pasteur, J., additional, Pralong, P., additional, Nosbaum, A., additional, Droitcourt, C., additional, Viguier, M., additional, Tauber, M., additional, Seneschal, J., additional, Barbarot, S., additional, and Staumont-Sallé, D., additional

Published
2022
Full Text
View/download PDF

26. Impact de la dermatite atopique sur les conjoints des patients

Author

Misery, L., primary, Seneschal, J., additional, Corgibet, F., additional, Halioua, B., additional, Marquie, A., additional, Merhand, S., additional, Le Fur, G., additional, Bergqvist, C., additional, Taieb, C., additional, Staumont-Sallé, D., additional, Ezzedine, K., additional, and Richard, M.A., additional

Published
2022
Full Text
View/download PDF

27. Efficacité et sécurité du lébrikizumab en association avec des dermocorticoïdes chez des patients atteints de dermatite atopique modérée à sévère : essai de phase 3, randomisé, contrôlé contre placebo (ADhere)

Author

Seneschal, J., primary, Simpson, E., additional, Gooderham, M., additional, Wollenberg, A., additional, Weidinger, S., additional, Armstrong, A., additional, Soung, J., additional, Ferrucci, S., additional, Gontijo, R., additional, Xu, W., additional, Witte, M.M., additional, and Blauvert, A., additional

Published
2022
Full Text
View/download PDF

28. Efficacité et sécurité du lébrikizumab dans le traitement de la dermatite atopique modérée à sévère : résultats de deux essais de phase 3, randomisés, en double insu, contrôlés contre placebo

Author

Silverberg, J.I., primary, Thaçi, D., additional, Seneschal, J., additional, Stein, L., additional, Blauvert, A., additional, Simpson, E., additional, Chu, C.Y., additional, Liu, Z.T., additional, Gontijo, R., additional, Pillai, S., additional, and Guttman-Yassky, E., additional

Published
2022
Full Text
View/download PDF

31. Blépharo-conjonctivites sous dupilumab : recommandations du groupe CEDRE. Dermatite atopique, conjonctivites et dupilumab

Author

Doan, S., Arnould, L., Febvay, C., Fournié, P., Gueudry, J., Labalette, P., Ouilhon, C., Tran, T.-H.-C., Vabres, B., Barbarot, S., Bouaziz, J.-D., Du-Thanh, A., Jachiet, M., Seneschal, J., Soria, A., Staumont-Sallé, D., Baudouin, C., Mortemousque, B., Service d'ophtalmologie [Hopital Bichat - Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Service d'Ophtalmologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Ophtalmologie [Hôpital Edouard Herriot - HCL]], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université Catholique de Lille - Faculté de Médecine, Maïeutique, Sciences de la santé (FMMS), Institut Catholique de Lille (ICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Inserm U1035, Biotherapies des Maladies Genetiques et Cancers, Univ Bordeaux, CHU de Bordeaux, Pole de Biologie et Pathologie, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO)

Subjects
Dermatite atopique, Conjonctivite, Atopic Dermatitis, Dupilumab, Conjunctivitis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Dupilumab is a recombinant monoclonal IgG4 type antibody which inhibits IL4 and IL13 signaling. It is indicated in moderate to severe atopic dermatitis (AD) in adults and adolescents over 12 years of age. Its side effects include conjunctivitis and blepharoconjunctivitis, affecting between 4.7% and 28% of patients depending on the study. The incidence of conjunctivitis in patients treated with dupilumab for AD appears to be higher than placebo in clinical studies. This increase was not observed in patients treated with dupilumab for asthma or sinonasal polyposis. The risk factors for conjunctivitis in patients with AD are disease severity, pre-existence of conjunctivitis and low concentrations of dupilumab, but the pathophysiology of this disease is poorly understood. A literature search carried out in April and May 2020 showed an increase in the number of publications on the subject, but there are currently no official joint dermatologist-ophthalmologist recommendations for prevention and management. The objective of this article is to provide an overview of the status of this subject, to address the main questions raised by this type of conjunctivitis and to suggest a course of action for starting and continuing treatment with dupilumab in patients with AD, according to the recommendations of the French Ophthalmologist/Dermatologist group CEDRE.

Published
2022

33. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce

Author

Bosma, A L, Musters, A H, Bloem, M, Gerbens, L A A, Middelkamp-Hup, M A, Haufe, E, Schmitt, J, Barbarot, S, Seneschal, J, Staumont-Sallé, D, Johansson, E K, Bradley, M, von Kobyletzki, L B, Vittrup, I, Ruge, I Frier, Thyssen, Jacob P, Vestergaard, C, de Vega, M, García-Doval, I, Chiricozzi, A, Stingeni, Luca, Calzavara-Pinton, Piergiacomo, Ardern-Jones, M R, Reynolds, N J, Flohr, C, Spuls, P I, Chiricozzi, A (ORCID:0000-0002-6739-0387), Bosma, A L, Musters, A H, Bloem, M, Gerbens, L A A, Middelkamp-Hup, M A, Haufe, E, Schmitt, J, Barbarot, S, Seneschal, J, Staumont-Sallé, D, Johansson, E K, Bradley, M, von Kobyletzki, L B, Vittrup, I, Ruge, I Frier, Thyssen, Jacob P, Vestergaard, C, de Vega, M, García-Doval, I, Chiricozzi, A, Stingeni, Luca, Calzavara-Pinton, Piergiacomo, Ardern-Jones, M R, Reynolds, N J, Flohr, C, Spuls, P I, and Chiricozzi, A (ORCID:0000-0002-6739-0387)

Published
2022

35. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score

Author

Stalder, J.‐F., Aubert, H., Anthoine, E., Futamura, M., Marcoux, D., Morren, M.‐A., Trzeciak, M., Szalai, Z., Veres, K., Deleuran, M., Vestergaard, C., Boralevi, F., Chu, C.‐Y., De Raeve, L., Svensson, Å., Fölster‐Holst, R., Buchner, M., Takaoka, R., Aoki, V., Chernyshov, P., Chernyshova, L., Murrell, D. F., Zhao, C., Mckinster, C. D., Von Kobyletzky, L., Eichenfield, L., Totri, C., Lio, P., Seneschal, J., Moret, L., and Barbarot, S.

Published
2017
Full Text
View/download PDF

36. European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C.P., Rudnicka, L., Frasin, L.A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, I., Frances, C., Jalili, A., Just, U., Kähäri, V., Kárpáti, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N.J., and Krieg, T.

Published
2017
Full Text
View/download PDF

37. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C.P., Rudnicka, L., Frasin, L.A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, I., Frances, C., Jalili, A., Just, U., Kähäri, V., Kárpáti, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N.J., and Krieg, T.

Published
2017
Full Text
View/download PDF

49. Les mutations ADAR1 entraînant un psoriasis sévère dépendant de l’interféron de type I : un biomarqueur en vue d’une médecine de précision

Author

Assan, F., Izmiryan, A., Tragin, M., Fremond, M.L., Di Domizio, J., Akroun, F., Mahé, E., Sbidian, E., Guégan, S., Aubin, F., Chang, M., Satishkumar, D., Costanzo, A., Bourrat, E., Seneschal, J., Sohier, P., Battistella, M., Guerrera, C., Bole, C., Nitschke, P., Crow, Y., Gilliet, M., Gudjonsson, J.E., and Bachelez, H.

Abstract

Peu de modèles monogéniques de psoriasis en plaques (PsO) ont été identifiés. Nous rapportons le rôle pathogène de variants perte de fonction du gène adénosine déaminase agissant sur l’ARN1 (ADAR1) dans une population de malades atteints de PsO.

Published
2024
Full Text
View/download PDF

50. Efficacité du dupilumab dans l’eczéma chronique des mains atopique et non atopique : résultats d’un essai clinique français, randomisé, multicentrique, contrôlé en double aveugle versus placebo

Author

Tauber, M., Du Thanh, A., Jendoubi, F., Bérard, E., Raison-Peyron, N., Bouznad, A., Konstantinou, M.P., Rioual, J., Boussier, M., Milpied, B., Bulai Livideanu, C., Jaulent, L., Hacard, F., Nosbaum, A., Seneschal, J., and Paul, C.

Abstract

L’eczéma chronique des mains (ECM) est une dermatose invalidante, d’origine multifactorielle intriquant trois grandes étiologies : la dermatite atopique (DA), la dermatite allergique de contact et la dermatite irritative de contact. Le dupilumab est utilisé en France depuis 2017 pour le traitement de la DA. L’objectif principal de l’étude était d’évaluer pour la première fois, l’efficacité et la tolérance du dupilumab chez des patients atteints d’ECM toutes étiologies et toutes morphologies confondues.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results